Partial Penectomy: Surgical Treatment for Penile Cancer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Partial penectomy is a surgical procedure in which the distal (end) portion of the penis is removed to achieve oncologically clear margins in the treatment of penile cancer. It is the most commonly performed surgical procedure for penile squamous cell carcinoma (SCC) involving the glans or distal shaft at clinical stages T2 and T3, where organ-sparing approaches cannot achieve adequate margins while maintaining adequate urethral function.

Penile cancer is a rare malignancy in high-income countries — incidence approximately 1–2 per 100,000 men per year — but is significantly more common in regions with lower circumcision rates, poor access to healthcare, and high prevalence of human papillomavirus (HPV) infection. It is predominantly a squamous cell carcinoma arising from the preputial epithelium or the mucosal surface of the glans and coronal sulcus.

The operation is performed under spinal or general anaesthesia. A tourniquet is applied at the base of the penis to reduce intraoperative bleeding. The dorsal and ventral penile skin is incised at the planned resection level — which is determined by the proximal extent of the primary tumour plus a minimum 5 mm clear histological margin, as recommended by the European Association of Urology (EAU) 2024 penile cancer guidelines. The corpora cavernosa are divided sharply and the urethra is spatulated to create a neomeatus, which is sutured to the divided skin edges to form a new urinary opening.

The amputated specimen is oriented and inked for the pathologist, who assesses histological margins and tumour grade. The procedure typically takes 60–90 minutes, and most patients are discharged home within 24–48 hours with a urinary catheter in place for 5–7 days while the neomeatus heals.

The decision to perform partial penectomy is based on the clinical and pathological staging of the primary tumour according to the AJCC 8th Edition / TNM classification for penile cancer, together with EAU guideline recommendations on organ preservation versus amputation:

• T1a (low-grade, no lymphovascular invasion): Organ-sparing procedures are strongly preferred. Options include wide local excision, glans resurfacing, laser ablation (Nd:YAG or CO2), and topical agents (5-fluorouracil, imiquimod) for carcinoma in situ (Tis) and T1a tumours. Glansectomy with split-skin graft reconstruction — removal of the entire glans with immediate coverage using a split-thickness skin graft — provides excellent oncological control and cosmetic outcomes for T1 tumours involving the glans and is the preferred organ-sparing surgery as per NICE guideline CG151 and EAU guidelines.
• T1b and T2 (invasion of corpus spongiosum or cavernosum without fixation): Partial penectomy is the standard of care when organ-sparing surgery cannot achieve a 5 mm clear margin. At this stage tumour has invaded the erectile tissue of the corpus spongiosum (T2 spongiosum) or corpus cavernosum (T2 cavernosum) but does not extend to the prostate or pubic bone.
• T3 (invasion of urethra): Urethral involvement necessitates partial or total penectomy depending on the length of urethral involvement and residual penile shaft length. Urinary reconstruction (perineal urethrostomy) is planned concurrently.
• T4 (invasion of adjacent structures — scrotum, prostate, pubis): Requires total penectomy with perineal urethrostomy. Outside the scope of partial penectomy.

Histological tumour grade is assessed using the ISUP (International Society of Urological Pathology) grading system: Grade 1 (well-differentiated), Grade 2 (moderately differentiated), and Grade 3 (poorly differentiated). Higher ISUP grade is independently associated with increased risk of inguinal lymph node metastasis and poorer disease-specific survival.

A thorough pre-operative evaluation is mandatory to correctly stage the disease, plan the extent of surgery, and assess fitness for the planned procedure:

• Clinical examination: The primary tumour is assessed for size, anatomical location (glans, prepuce, shaft), depth of invasion, fixation to underlying structures, and any satellite lesions. The inguinal lymph nodes are carefully palpated bilaterally; palpable nodes are documented as clinical N1 (mobile unilateral) or N2 (multiple/bilateral) or N3 (fixed/skin involvement).
• Penile MRI: High-resolution MRI of the penis in pharmacological erection (intracavernosal prostaglandin E1 injection) is the most accurate non-invasive method for assessing depth of corpus cavernosum invasion and informing the boundary between organ-sparing and amputation surgery. It achieves sensitivity of 75–86% and specificity of 89% for invasion depth.
• Biopsy and histological grading: An incisional biopsy of the primary tumour under local anaesthetic provides definitive tissue diagnosis and ISUP grade. Occasionally the primary lesion is excised as an excisional biopsy with definitive histology guiding the need for re-excision.
• Inguinal lymph node staging: All patients with T1G2 or higher tumours require staging of the inguinal nodes. In cN0 patients (clinically and radiologically node-negative), dynamic sentinel node biopsy (DSNB) is the recommended staging procedure at specialist centres. CT of the abdomen and pelvis and PET-CT are used to assess pelvic and distant nodes in cN+ disease.
• Anaesthetic assessment: Blood tests, ECG, and review of medications (particularly antiplatelet agents and anticoagulants that must be stopped pre-operatively) are performed at the pre-assessment clinic.

All cases are reviewed at a penile cancer multidisciplinary team (MDT) meeting before definitive surgery, as recommended by NICE guideline CG151 (2002, updated) and EAU guidelines (2024).

Primary Tumour Surgery:

• Wide local excision: For T1a tumours, removal of the lesion with a 5 mm margin of healthy tissue. Defects up to 2 cm can often be closed primarily; larger defects may require a split-skin or full-thickness skin graft.
• Glansectomy with split-skin graft: Complete removal of the glans penis for T1 and selected T2 tumours that involve the glans but do not deeply invade the corpora cavernosa. A split-thickness skin graft harvested from the inner thigh is sutured over the exposed tips of the corpora cavernosa and urethra, forming a cosmetically acceptable and functional neoglans. Local recurrence rate is approximately 5–8%.
• Partial penectomy: Amputation of the distal penis at a level that achieves at least 5 mm of histologically clear proximal margin. The retained penile stump must be long enough (ideally at least 3 cm) to allow voiding while standing. The spatulated urethra is fixed to the skin edges as a neomeatus. The cut ends of the corpora cavernosa are oversewn with absorbable sutures.
• Total penectomy with perineal urethrostomy: Required for T3/T4 tumours involving the proximal shaft or when partial penectomy cannot achieve clear margins with an adequate residual stump. A perineal urethrostomy is created to redirect urine to a perineal opening.

Inguinal Lymph Node Management:

• Dynamic sentinel node biopsy (DSNB): Recommended for cN0 patients with T1G2 or higher tumours at specialist centres. Technetium-99m nanocolloid is injected around the primary tumour 24 hours pre-operatively; sentinel nodes are identified using a handheld gamma probe intraoperatively and confirmed with patent blue dye. Sensitivity for occult nodal metastases exceeds 88% at high-volume centres.
• Modified inguinal lymph node dissection (modified ILND): Performed when DSNB is not available or when the sentinel node is positive. It removes a defined anatomical template of inguinal nodes (superficial and deep) within the femoral triangle while preserving the saphenous vein to reduce lymphoedema incidence (from 50% with radical dissection to approximately 10–15% with modified technique).
• Pelvic lymph node dissection: Added for patients with more than two positive inguinal nodes or extranodal extension.

Partial penectomy, when performed with correct oncological technique at an appropriate stage of disease, offers the following significant benefits:

• High local disease control: The local recurrence rate after partial penectomy is 4–8%, substantially lower than after glansectomy (8–12%) or wide local excision (10–20%). Clear histological margins — the primary determinant of local control — are more reliably achieved with partial amputation than with organ-sparing techniques for T2 tumours.
• Excellent cancer-specific survival in node-negative disease: For patients with pN0 disease after formal lymph node staging, 5-year cancer-specific survival following partial penectomy is approximately 85–95% for T2 tumours, reflecting the high rate of disease control achievable at this stage with correct surgery.
• Preserved voiding function: Unlike total penectomy — which requires a perineal urethrostomy through which the patient must void sitting down — partial penectomy with neomeatus creation usually allows voiding while standing when the retained penile stump is 3 cm or longer. This has a significant positive impact on quality of life and social functioning.
• Potential for sexual activity: Studies from specialist penile cancer centres report that 40–60% of men retain the ability to engage in some form of sexual activity (including penetrative intercourse with a shortened penis or prosthetic aid) after partial penectomy, particularly when the stump length exceeds 4–5 cm.
• Definitive specimen for histology: The surgical specimen provides complete pathological staging, accurate margin assessment, and ISUP grading to guide adjuvant lymph node treatment decisions and long-term surveillance intensity.

Both surgical and oncological risks must be discussed in detail with patients before proceeding to partial penectomy:

• Local recurrence: Approximately 4–8% of patients develop local recurrence at the penile stump or neomeatus, typically within 2 years of surgery. Local recurrence after partial penectomy can be managed with revision amputation (completion penectomy) in most cases, and salvage oncological outcomes are generally satisfactory when recurrence is detected early through scheduled surveillance.
• Meatal stenosis: Narrowing of the urethral neomeatus occurs in approximately 5–20% of patients and may cause a thin, deflected, or obstructed urinary stream. Management ranges from intermittent self-dilation to formal surgical meatotomy or meatoplasty under local anaesthetic.
• Wound complications: Wound haematoma, infection, and delayed healing at the stump site are reported in 5–10% of patients. Meticulous haemostasis, tension-free wound closure, and perioperative antibiotics reduce the risk.
• Lymphoedema of the lower limbs and scrotum: A significant complication primarily related to inguinal lymph node dissection rather than the penile surgery itself. Incidence after modified inguinal lymph node dissection is approximately 10–15%, compared to 30–50% after radical template dissection. Long-term compression garments and physiotherapy-led manual lymphatic drainage are the mainstays of management.
• Psychological impact and body image: The physical alteration caused by penile amputation — even partial — frequently leads to significant distress, loss of male identity, depression, and anxiety. Studies report that psychological morbidity is often greater than physical morbidity, underscoring the importance of specialist psychosexual counselling as a core component of post-operative care.
• Sexual dysfunction: Partial penectomy invariably alters sexual function, particularly for penetrative intercourse. The degree of functional impact correlates directly with the length of residual penile stump. Shortened stump length, absence of the glans, and altered penile sensation all contribute to erectile dysfunction and reduced sexual satisfaction.

Structured post-operative follow-up is essential for early detection of local recurrence, management of treatment-related side effects, and support of psychosexual rehabilitation:

• Immediate post-operative care: A urinary catheter is left in situ for 5–7 days to allow the spatulated urethral neomeatus to heal. The wound is managed with light non-adherent dressings. Post-operative pain is managed with regular paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and short-course opioids. Most patients are discharged home on day 1–2.
• Catheter removal: The catheter is removed in the outpatient clinic at day 5–7. The patient voids to demonstrate an adequate urinary stream. If meatal stenosis is evident early, dilation is initiated promptly.
• Wound review and histology discussion: A 2–4 week post-operative appointment reviews wound healing and discusses the final histopathological report, including margin status, ISUP grade, perineural invasion, and lymphovascular invasion. This informs the plan for lymph node management if not yet completed.
• Oncological surveillance: EAU guidelines recommend clinical examination of the penile stump and inguinal nodes every 3 months for the first 2 years, then every 6 months to year 5, then annually. MRI of the penis (or stump) at 12 months provides a baseline for future comparison. Imaging of the inguinal and pelvic nodes is added at each surveillance visit for patients who had positive nodes.
• Psychosexual rehabilitation: All patients should be offered referral to a specialist in psychosexual medicine or a clinical psychologist with expertise in cancer-related body image and sexual dysfunction. Penile prosthesis implantation (inflatable penile prosthesis IPP) into residual corporal tissue is feasible in selected patients with adequate stump length and may restore penetrative capability. Vacuum erection devices and intimate partner counselling also form part of the rehabilitation programme.
• HPV vaccination and smoking cessation: Partners of patients with HPV-related penile cancer may benefit from HPV vaccination discussion. Smoking cessation support is strongly encouraged as smoking is an independent risk factor for recurrence and second primary tumours.

The cost of surgical treatment for penile cancer involves multiple components beyond the primary penile surgery itself:

• Primary surgical procedure: Partial penectomy under general or spinal anaesthesia at a private hospital costs approximately USD 8,000–15,000 in the United States, EUR 4,000–9,000 in Western Europe, and USD 2,000–4,500 in medical tourism destinations including India and Thailand at JCI-accredited centres. These figures typically include the operation, anaesthesia, and a 2-night hospital stay.
• Dynamic sentinel node biopsy (DSNB): This specialist nuclear medicine-guided procedure, performed simultaneously with primary penile surgery at most centres, adds USD 2,000–5,000 to the total cost due to the requirement for radioisotope tracers, a gamma camera scan, and specialised surgical team expertise.
• Inguinal lymph node dissection: Modified or radical ILND if clinically indicated adds operating time and hospital stay, typically increasing the total surgical bill by 40–70%.
• Pathological analysis: Comprehensive histopathological assessment including ISUP grading, immunohistochemistry (p16, p53, Ki-67), and margin mapping is charged separately in many healthcare systems and is an essential component of the total cost.
• Penile prosthesis: For patients who wish to pursue penile prosthesis implantation as part of sexual rehabilitation, the device and surgery together cost USD 12,000–25,000 in the United States or USD 4,000–8,000 in India or Thailand. Inflatable three-piece devices command a significant premium over malleable rod implants.
• Psychosexual counselling: An often-overlooked cost component; structured psychosexual rehabilitation involving 4–8 sessions with a specialist psychologist or sexual health therapist is an important investment in quality of life recovery.

International patients should confirm whether package prices include DSNB, pathology fees, post-operative catheter care, and follow-up visits before committing to a treatment destination.

Organ-sparing alternatives to partial penectomy are actively preferred whenever oncological safety can be maintained. The choice of approach is guided by tumour stage, grade, size, and anatomical location:

• Glansectomy with split-skin graft reconstruction: The EAU-recommended organ-sparing procedure for T1 and selected early T2 tumours confined to the glans. The entire glans is excised and the exposed corporeal tips are resurfaced with a split-thickness skin graft harvested from the inner thigh. Results in an acceptable cosmetic and functional outcome with local recurrence rates of 5–8% at high-volume centres. NICE guidelines and EAU penile cancer guidelines (2024) recommend this over partial penectomy for eligible T1 tumours.
• Wide local excision: Suitable for small, well-localised T1 tumours where a 5 mm clear margin can be achieved without functional compromise. Often combined with a skin graft or local flap reconstruction for larger defects.
• Laser ablation (CO2 or Nd:YAG laser): Effective for carcinoma in situ (Tis/pTis), T1a tumours, and condylomatous lesions. Low morbidity and excellent cosmetic results. Requires access to specialist laser equipment and careful patient selection. Local recurrence rate for pTis: approximately 10–15%; requires close long-term surveillance.
• Brachytherapy: High-dose-rate (HDR) or low-dose-rate (LDR) penile brachytherapy for T1 and small T2 tumours confined to the glans achieves 5-year local control rates of 70–85%, comparable to surgery in selected patients, while preserving penile appearance and function. Available at a small number of specialist centres. Not appropriate for invasive tumours with deep corpus involvement.
• External beam radiotherapy (EBRT): Rarely used as a primary modality for penile cancer due to inferior local control compared to surgery. Reserved for patients unfit for or refusing surgery. Carries a significant risk of late radiation fibrosis, meatal stenosis, and — rarely — radiation necrosis requiring salvage penectomy.